Demographics of a large cohort of urban chronic hepatitis C patients

Hepatology International

Volumn 2, Issue 3, 2008, Pages 376-381

  Siddiqui, Firdous A ^a   Ehrinpreis, Murray N ^a   Janisse, James ^a   Dhar, Ravi ^a   May, Elizabeth ^a   Mutchnick, Milton G ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

African Americans; Chronic hepatitis C; Demographics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS C ANTIBODY;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COHORT ANALYSIS; COMORBIDITY; DEMOGRAPHY; FEMALE; GENOTYPE; HEPATITIS C; HISPANIC; HUMAN; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SEX DIFFERENCE; URBAN AREA; VIRUS LOAD;

EID: 51049093176     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9086-x     Document Type: Article

References (32)

1. Edlin BR. Five million Americans infected with the Hepatitis C virus: A corrected estimate. Hepatology 2005;42(4, Suppl 1):44
2. Alter MJ, Jruzon-Moran MS, Nanina O, Mcquillan GM, Gao F, Margolis H, et al. The prevalence of hepatitis C infection in the United States, 1988 through 1994. New Engl J Med 1999;341:556-562
3. Poynard T, Yuen M, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003;362:2095-2100
4. Wiley TE, Brown J, Chan J. Hepatitis C infection in African-Americans: its natural history and histological progression. Am J Gastroenterol 2002;97:700-706
5. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004;117:163-168
6. Samuel D. Chronic hepatitis C treatment patterns in African-Americans: an update. Am J Gastroenterol 2005;100:716-722
7. Muir AJ, Bornstein JD, Killenberg PG. Atlantic coast hepatitis treatment group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350(22):2265-2271
8. Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Lybik M, et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 2001;8:264-269
9. Khan A, Mutchnick M, Ehrinpreis M, Dhar R, Siddiqui F. African-Americans with genotype-1 with chronic hepatitis C respond poorly to pegylated-interferon and ribavirin combination treatment as compared to Caucasians. Am J Gastroenterol 2005;100(Suppl):311
10. Conjeevaram HS, Fried MW, Jeffers LJ, Terralt N, Wiley-Lucas TE, Afdal N, et al. Peg-interferon alfa-2a and ribavirin in African-American and Caucasian patients with chronic hepatitis C, genotype 1. Gastroenterology 2006;131(2):470-477
11. Nguyen HA, Miller AI, Dieperink E, Willenbring ML, Tetrick LL, Durfee JM, et al. Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 2002;97:1813-1820
12. Cheung RC, Currie S, Shen H, Ho SB, Bini EJ, Wright TL, et al. VA HCV-001 Study Group. Chronic hepatitis C in Latinos: Natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 2005;100:2186-2193
13. Celona AF, Yu MC, Prakash M, Kuo T, Bonacini M. Hepatitis C in a Los Angeles public hepatitis clinic: Demographic and biochemical differences associated with race-ethnicity. Clin Gastroenterol Hepatol 2004;2:459-462
14. Howell C, Jeffers L, Hoofnagle J. Hepatitis C in African-Americans: summary of a workshop. Gastroenterology 2000;119:1385-1396
15. Crosse K, Onuora GU, Anania F, Laurin J, Papadimitriou J, Drachenberg C, et al. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clinical Gastroenterol Hepatol 2004;2:463-468
16. Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004;2:469-473
17. Pearlman BL. Hepatitis C virus infection in African Americans. Clin Infect Dis 2006;42(1):82-91
18. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in response to therapy with Interferon in CHC. Hepatology 1999;30:787-793
19. Fleckenstein J. Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep 2004;6(1):66-70
20. Bedossa P, Poynard T, for the French METAVIR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C. Hepatology 1996;24:2889-2893
21. Man RE, Smart RG, Auglin L, Adlef EM. Reduction in cirrhosis deaths in the US: Association with per capita consumption and AA membership. J Study Alcohol 1991;52:361-365
22. El Serag HB, Mason A. Rising incidence of HCC in US. N Engl J Med 1999;340:745-756
23. Nyugen MH, Whittemore AS, Garcia RT, Tawfeek SA, Ning J, Lam S, et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2004;2:820-824
24. El-Serag HB. Hepatocellular carcinoma. Recent trends in United States. Gastroenterology 2004;127:S27-S34
25. Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol 2001;96:858-863
26. Buffington J, Damon S, Moyer L, Culver D. CDC, Atlanta, GA. Racial differences in the knowledge regarding hepatitis C virus infection. JAMA 2000;284:1651-1652
27. McHutchinson JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, et al. The impact of interferon plus ribavirin on response to treatment in black patients with chronic hepatitis C. Gastroenterology 2000;119:1317-1323
28. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kD) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004;39:1702-1708
29. Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in special populations: Patient and treatment considerations. Clin Gastroenterol Hepatol 2005;3:311-318
30. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham N, Sterling RK, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008;47:789-798
31. Snyder N, Gajula L, Xiao SY, Grady J, Luxon, Lau DT, et al. APRI: An easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 2006;40(6):535-542
32. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase to platelet ratio index for the prediction of hepatitis C-related fibrosis: A systematic review. Hepatology 2007;46(3):912-921